Who are Systemic Dexamethasone plus perineural bupivacaine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/systemic-dexamethasone-plus-perineural-bupivacaine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Systemic Dexamethasone plus perineural bupivacaine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Systemic Dexamethasone plus perineural bupivacaine (Systemic Dexamethasone plus perineural bupivacaine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: corticosteroid + local anesthetic. Area: Pain management / Regional anesthesia.

marketed Combination therapy: corticosteroid + local anesthetic Glucocorticoid receptor (dexamethasone); voltage-gated sodium channels (bupivacaine) Pain management / Regional anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Systemic Dexamethasone plus perineural bupivacaine (Systemic Dexamethasone plus perineural bupivacaine) — Sherif Mohamed Abd el moneim Soaida, MD. Systemic dexamethasone reduces inflammation while perineural bupivacaine provides local anesthetic blockade of nerve conduction at the injection site.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Systemic Dexamethasone plus perineural bupivacaine TARGET	Systemic Dexamethasone plus perineural bupivacaine	Sherif Mohamed Abd el moneim Soaida, MD	marketed	Combination therapy: corticosteroid + local anesthetic	Glucocorticoid receptor (dexamethasone); voltage-gated sodium channels (bupivacaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: corticosteroid + local anesthetic class)

Sherif Mohamed Abd el moneim Soaida, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Systemic Dexamethasone plus perineural bupivacaine — Competitive Intelligence Brief. https://druglandscape.com/ci/systemic-dexamethasone-plus-perineural-bupivacaine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab